Physician profile
Ying Peng
NPI 1528156429
$18,337.26
in general payments reported to CMS, 2019-2025
54 companies · $3,532 in 2025
The $3,532 reported for 2025 was more than what 92% of Neurodevelopmental Disabilities (Pediatrics) providers received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $1,622 · 2021: $2,145 · 2022: $2,142 · 2023: $3,303 · 2024: $3,659 · 2025: $3,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,368.43 |
| Education | $125.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,040.74 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Tris Pharma INC | $1,256.01 | 2019-2025 | Quillichew Er, Dyanavel Xr, Onyda Xr |
| Alexion Pharmaceuticals, INC. | $994.56 | 2019-2025 | Ultomiris |
| Neurelis, INC. | $799.32 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $793.47 | 2019-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Argenx US, INC. | $748.95 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Grifols USA, LLC | $694.16 | 2019-2025 | Gamunex-C |
| Emd Serono, INC. | $675.62 | 2019-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $654.00 | 2020-2025 | Xcopri |
| Csl Behring | $591.51 | 2019-2025 | Hizentra |
| Jazz Pharmaceuticals INC. | $567.49 | 2019-2025 | |
| Pfizer INC. | $538.84 | 2021-2025 | |
| Abbvie INC. | $536.93 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $479.82 | 2019-2024 | Jornay Pm |
| Octapharma USA, INC. | $442.13 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.